Over-expression of chromatin assembly factor 1 subunit A (CHAF1A) facilitates cell proliferation in non-small cell lung cancer (NSCLC)

Figures & data

Table 1. Clinical and pathological data.

	N	Percentage (%)
Gender
Male	95	77.24
Female	28	22.76
Age
<60 years	76	61.79
≥60 years	47	38.21
Pathological type
Squamous cell carcinoma	57	46.34
Adenocarcinoma	66	53.66
Differentiation degree
II	61	49.59
III	62	50.41
Tumour size
<3 cm	21	17.07
≥3 cm, < 5 cm	61	49.59
≥5 cm	41	33.33
H-score
<P10=0	23	18.70
≥P10=1	100	81.30
Clinical staging
I	41	33.33
II	50	40.65
III–IV	32	26.02
Vessel invasion
No	109	88.62
Yes	14	11.38
Smoking
No	73	59.35
Yes	50	40.65
Lymphatic metastasis
No	73	59.35
Yes	50	40.65
5-year survival
Survived	73	59.35
Died	50	40.65
5-year disease-free survival
Without recurrence	58	47.15
With recurrence	65	52.85

Figure 1. Over-expression of CHAF1A in NSCLC tissues and lung cancer cell lines. (A) Immunohistochemical staining of NSCLC tissues (scale bar: 100 μm). (B) H-score analysis of CHAF1A in NSCLC tissues. Compared with the normal control group, *P < 0.05, **P < 0.05, and ***P < 0.05.

Figure 2. Over-expression of CHAF1A correlates with poor prognosis of NSCLC. Kaplan–Meier curves for the high-expression (A) and low-expression (B) groups.

Table 2. Log-rank test of disease-free survival and total survival of NSCLC patients.

	Disease-free survival				Overall survival
	Death	Survival	χ^2	P	Death	Survival	χ^2	P
Gender
Male	45	50	4.639	0.031	35	60	1.938	0.164
Female	20	8			15	13
Pathological type
Squamous cell carcinoma	23	34	6.902	0.009	19	38	2.123	0.145
Adenocarcinoma	42	24			31	35
Differentiation degree
II	25	36	7.945	0.005	20	41	3.836	0.050
III	40	22			30	32
Tumour size
<3 cm	8	13	8.285	0.016	4	17	6.435	0.040
≥3 cm, <5 cm	30	31			25	36
≥5 cm	27	14			21	20
Lymphatic metastasis
No	26	47	24.046	< 0.001	18	55	22.199	< 0.001
Yes	39	11			32	18
Clinical staging
I	13	28	34.712	< 0.001	8	33	22.855	< 0.001
II	24	26			20	30
III–IV	28	4			22	10
Vessel invasion
No	57	52	0.127	0.721	44	65	0.035	0.852
Yes	8	6			6	8
Smoking
No	24	17	0.354	0.552	20	21	1.108	0.293
Yes	41	40			30	51
H-score
<P10	6	17	7.581	0.006	46	54	5.951	0.015
≥P10	59	41			4	19

Table 3. COX regression analysis.

	5-year disease-free survival		5-year overall survival
	RR (95.0% CI)	P	RR (95.0% CI)	P
Gender	1.978 (1.076, 3.637)	0.028	1.796 (0.969, 3.330)	0.063
Pathological type	2.242 (1.243, 4.044)	0.007
Differentiation degree	2.385 (1.375, 4.139)	0.002
Clinical staging		0.001		0.112
II	1.632 (0.802, 3.321)	0.177	1.712 (0.681, 4.306)	0.253
III–IV	3.597 (1.746, 7.412)	0.001	2.933 (1.014, 8.482)	0.047
Lymphatic metastasis			1.982 (0.922, 4.262)	0.080
Tumour size		0.088
Tumour size (2)	2.141 (0.923, 4.964)	0.076
Tumour size (3)	2.656 (1.112, 6.347)	0.028
H-score	3.458 (1.447, 8.265)	0.005	3.059 (1.085, 8.622)	0.034

Figure 3. CHAF1A knock-down inhibits proliferation of lung cancer cells. (A) Knock-down efficiency detected by quantitative real-time PCR analysis. Compared with the control group, ** P < 0.01. (B) Cell proliferation assessed at 1–5 days in H1299 cells transfected with CHAF1A-siRNA lentivirus. (C) H1299 cell counts at G1, S and G2/M cell cycle phases detected by flow cytometry at day 5 after CHAF1A-siRNA transfection. (D) Cell clone counts at days 1–3 after CHAF1A-siRNA transfection. (E) Cell colony formation. (F) Apoptotic rate. Compared with the control group, *** P < 0.001.